CORCEPT THERAPEUTICS INC

Key metrics

Financial performance

Over the last 9 fiscal years CORCEPT THERAPEUTICS INC's revenue grew from $81.32M to $761.41M, a compound annual growth rate of 28.2%. Net profit margin expanded from 10.0% to 13.1% over the same period - every figure below comes from the company's audited annual filings.

Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.

Key statistics

Latest filings

Browse the full filing history (1,955 filings)

Recent press releases

• Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure2026-05-29

  Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure – Corcept Therapeutics, Incorporated

• Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome2026-05-27

  Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome – Corcept Therapeutics, Incorporated

• Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update2026-04-30

  Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update – Corcept Therapeutics, Incorporated

• Corcept Phase 2 Study Dazucorilant Demonstrates Two Year Overall2026-04-30

  Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis – Corcept Therapeutics, Incorporated

• Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call2026-04-23

  Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call – Corcept Therapeutics, Incorporated

Similar companies

The largest companies sharing CORCEPT THERAPEUTICS INC's SEC industry classification (pharmaceutical preparations).